News Quantified

PLX – protalix biotherapeutics, inc. (de) (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Protalix BioTherapeutics, Inc. (NYSE: PLX) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.

Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]

Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results [Yahoo! Finance]

Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results

Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024 [Yahoo! Finance]

-21.4%

BEAT

9.2%

BEAT

Form DEF 14A Protalix BioTherapeutics For: Jun 27

Form 4 Protalix BioTherapeutics For: Apr 01 Filed by: Bashan Dror

Form 10-K Protalix BioTherapeutics For: Dec 31

Form 8-K Protalix BioTherapeutics For: Mar 14

Top News Gainers

10/17 Protalix BioTherapeutics Announces Positive 12-Month Interim Data From the BRIDGE Phase III Open Label Switch-over Study of Pegunigalsidase Alfa for the Treatment of Fabry Disease 65.8%

11/18 Protalix BioTherapeutics and Chiesi Farmaceutici Announce Successful pre-BLA Meeting with FDA for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States 35.8%

6/6 Protalix BioTherapeutics and Chiesi Farmaceutici S.p.A to Apply for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States 35.2%

4/13 Form 4 Protalix BioTherapeutics For: Apr 07 Filed by: Schwartz Aharon 21.2%

1/3 Form 3 Protalix BioTherapeutics For: Jan 01 Filed by: Melincoff Gwen A 18.2%

3/23 Form SC 13G Protalix BioTherapeutics Filed by: HIGHBRIDGE CAPITAL MANAGEMENT LLC 8.3%

4/17 Form S-3 Protalix BioTherapeutics 7.7%

11/27 Protalix BioTherapeutics Hosting Key Opinion Leader Meeting on PRX-102 Drug Candidate for the Treatment of Fabry Disease 7.5%

3/5 Protalix BioTherapeutics to Hold Fourth Quarter and Full-Year 2019 Financial and Business Results Conference Call on March 12, 2020 7.3%

8/22 Protalix BioTherapeutics Focuses on Evaluating and Pursuing Alternatives to Maximize Shareholder Value through Refinancing & Strategic Partnerships 6.2%

Top News Decliners

8/8 Form 8-K Protalix BioTherapeutics For: Aug 08 -40.2%

4/30 Form EFFECT Protalix BioTherapeutics -17.2%

2/6 Form 8-K Protalix BioTherapeutics For: Feb 06 -9.0%

3/12 Form 10-K Protalix BioTherapeutics For: Dec 31 -8.4%

3/12 Protalix BioTherapeutics Reports Fourth Quarter and Full Year 2019 Financial and Business Results -7.4%

10/4 Form PRE 14A Protalix BioTherapeutics For: Dec 09 -7.2%

5/6 Form 8-K Protalix BioTherapeutics For: May 06 -6.9%

7/29 Protalix BioTherapeutics Appoints Eyal Rubin as its New Senior Vice President and Chief Financial Officer -6.0%

8/13 Shlomo Yanai Resigns as Chairman of the Board of Protalix BioTherapeutics -5.7%

8/30 Protalix BioTherapeutics Receives Listing Deficiency Letter from NYSE American -5.7%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day